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Purpose: Crystallins are major functional and structural proteins in mammalian lens. Their expression, distribution, and
protein–protein interaction affect lens development and fiber cell differentiation. Mutated crystallins lead to structural and
functional changes of lens structure and could lead to opacity formation and cataract development. The purpose of this
study was to investigate the biological effects of the cataract-causing G98R mutation on the αA-crystallin (CRYAA)
protein and to test the capability of chemical chaperone trimethylamine N-oxide (TMAO) to reverse such effects.Methods:
Myc/His-tagged, human, full-length, wild-type (WT) or G98R CRYAA was expressed in human lens epithelial B3 cells
and treated or not treated with TMAO. Triton X-100 (Tx) solubility and cellular localization of CRYAA were examined
by western blotting and confocal immunofluorescence, respectively. Ubiquitin proteasome-associated degradation was
assayed by MG132 treatment. Endoplasmic reticulum (ER) stress, unfolded protein response, and apoptosis were analyzed
by the expression of phosphorylated protein kinase-like ER-kinase, binding immunoglobulin protein (BiP), C/EBP
homologous  protein/growth  arrest  and  DNA  damage-inducible  gene  153  (CHOP/GADD153),  and  caspase-3  and
immunocytochemistry. Changes in heat shock and stress signaling were investigated.Results: When transfected in lens
epithelial B3 cells, unlike WT CRYAA located in the cytoplasm, the G98R CRYAA mutant formed aggregates inside the
ER and the protein was predominantly Tx-insoluble. ER stress was induced by G98R CRYAA expression, and cells
underwent apoptosis, as shown by a more frequent appearance of fragmented nuclei. Treatment with TMAO reduced Tx-
insoluble  mutant  protein  in  time-  and  dose-dependent  manners.  Other  chemical  chaperones,  4-phenylbutyric  acid,
dimethysulfoxide, and glycerol, were much less effective than TMAO. ER-associated aggregates were reduced after
TMAO treatment, and the protein was degraded through the ubiquitin–proteasome pathway. This alleviated ER stress and
resulted in less apoptosis. Moreover, TMAO treatment induced a moderate upregulation of heat shock protein 70,
indicating its effect on heat-shock response to modulate protein folding and assembly. No change was found for
nontransfected cells after TMAO treatment.Conclusion: The natural osmolyte and chemical chaperone TMAO reduced
the aggregation of G98R CRYAA. This alleviated ER stress and rescued the affected cells from apoptosis. Our results
showed that the chemical chaperone reduces mutant CRYAA aggregates in lens cells. We suggest a potential chemical-
based strategy to reduce lens opacity formation.
Lens  crystallins  are  a  major  family  of  water-soluble
functional  and  structural  proteins.  Their  expression,
distribution, and protein–protein interaction are crucial for
lens development and fiber cell differentiation [1]. Short-
range ordering existing between the tightly packed native
crystallin  protein  in  lens  fiber  cells  maintains  a  minimal
solution turbidity and a high degree of light transmission,
hence contributing to the transparency of lens [2]. Changes in
structural and functional properties of crystallins could cause
the breakdown of lens microstructure and result in a variation
of the refractive index and light scattering [3]. Mutations in
crystallin  genes  that  cause  the  production  of  aggregated
crystallins  in  the  state  of  modified,  damaged,  or  partially
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unfolded protein structures could lead to opacity formation
and cataract development [4,5].
Insolubility of crystallin proteins and formation of large
protein  aggregates  are  the  major  factors  that  lead  to  lens
opacity formation [6]. α-Crystallin is a predominant structural
and functional protein, comprising up to 40% of lens proteins.
It is composed of two subunits, αA- and αB-crystallin. Native
αA-crystallin (CRYAA) is a member of the small heat-shock
protein (hsp) family present in both ocular and nonocular
tissues [7-9]. It exhibits chaperone-like activity to suppress
the thermally induced aggregation of β- and γ-crystallins, the
two major structural lens proteins [10-13], and to protect them
from  inactivation  [14,15].  This  capability  underscores  the
importance of CRYAA in lens development and maintenance
of  transparency.  Loss  of  chaperoning  activity  in  mutant
CRYAA results in the formation of aggregates encompassing
its  substrate  proteins  [16].  These  intracellular  protein
aggregates adversely affect normal cell metabolism, lens fiber
cell differentiation, and cell survival, leading to abnormal
light  scattering  in  lens  structure  and  possibly  cataract
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2829development  [17-19].  Besides  the  W9X  mutation  causing
almost  complete  truncation  of  protein  [20],  other  known
congenital  cataract-causing  CRYAA  mutations  (R12C,
R21L, R49C, R54C, G98R, and R116C) are conserved in the
modification of arginine residues. Hence, the encoded mutant
proteins could have altered positive charges, conformational
changes, and/or loss of chaperoning activity [21-27]. G98R
CRYAA  was  reported  to  segregate  with  presenile  onset
cataract in an Indian family with disease onset at the age of
16 [25]. Purified G98R CRYAA protein was misfolded and
aggregation prone due to the exposed hydrophobic peptide
patches  and  lacked  the  corrective  activity  for  DL-
dithiothreitol (DTT)-induced aggregation of insulin [19,28].
In  this  study,  we  expressed  mutant  CRYAA  proteins,
including G98R, in human lens epithelial B3 cells to study
their solubility, aggregation, localization in organelles, and
apoptotic effects. We tested if the defective protein properties
could be resolved by treatment with chemical chaperones.
METHODS
Expression constructs and mutagenesis: A 548-bp EcoRI/
XhoI fragment encompassing the full-length 519 bp open
reading frame of CRYAA was ligated into the EcoRI/XhoI sites
of  a  mammalian  expression  plasmid  pcDNA6-His/myc
(Invitrogen, Carlsbad, CA) to obtain the construct pHis/myc-
CRYAAWT. This cloned fragment was used as a template to
generate specific mutations of CRYAA, using QuikChange II
Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA) and
oligonucleotides  (Table  1).  Wild-type  (WT)  and  mutant
constructs were verified by direct sequencing.
Cell culture and transfection: Human lens epithelial B3 cells
(American Tissue Culture Collection, Manassas, VA) were
cultured in Eagle’s Minimal Essential medium (Invitrogen)
supplemented with 10% fetal bovine serum (Invitrogen) and
antibiotics  (100  units/ml  penicillin  G  and  100  μg/ml
streptomycin sulfate, Invitrogen). Cells (105 cells/cm2) were
transfected with CRYAA constructs by using FuGene HD
transfection  reagent  (Roche,  Basel,  Switzerland)  at  an
optimized ratio of 3 μl FuGene per μg DNA in Opti-MEM® I
(Invitrogen) supplemented with GlutaMAXTM-I (Invitrogen).
Chemical chaperone treatments were started at 24 h after
transfection.
Treatment  by  trimethylamine  N-oxide  and  other  chemical
chaperone  molecules:  Trimethylamine  N-oxide  (TMAO)
(25–300 mM; Sigma, St Louis, MO), 4-phenylbutyric acid (4-
PBA;  0.2–2  mM;  tributyrate;  Triple  Crown  America  Inc,
Perkasie, PA), glycerol (1–5%; Sigma), or dimethylsulfoxide
(DMSO; 0.5–1%; Sigma) was added to the transfected cells.
Fresh culture medium containing drugs was replenished every
2 days.
Protein  analysis:  Cells  were  lysed  at  a  concentration  of
2.5×106  cells/ml  radioimmunoprecipitation  (RIPA)  buffer
containing  50  mM  Tris-HCl  (Sigma),  150  mM  sodium
chloride,  1%  Nonidet  P-40  (Sigma),  0.25%  sodium
deoxycholate (Sigma), protease inhibitor cocktail (Roche),
and 1 mM phenylmethyl sulfonylfluoride (PMSF; Sigma) for
30  min  on  ice.  After  centrifugation,  the  supernatant  was
collected  and  denatured  in  sample  buffer  with  a  final
concentration of 2% sodium dodecyl sulfate (SDS; BioRad,
Hercules, CA) and 50 mM DTT (Sigma). The cell pellet was
washed  with  ice-cold  PBS  and  denatured  in  SDS  sample
buffer containing 9 M urea (BioRad).
For  Triton  X-100  (Tx)  solubility  analysis,  cells  were
washed twice with ice-cold PBS and added to lysis buffer,
which contained 100 mM Tris-HCl (pH 7.4), 3 mM ethylene
glycol tetraacetic acid (EGTA; Sigma), 5 mM MgCl2, 0.5%
Triton X-100 (Tx; Sigma), protease inhibitor cocktail, and 1
mM  PMSF  at  5×106  cells/ml,  for  2  min  on  ice.  After
centrifugation, the supernatant containing Tx-soluble protein
was  denatured  in  SDS  buffer.  The  pellet  containing  Tx-
insoluble  protein  was  washed  twice  with  ice-cold  PBS,
sonicated,  and  denatured  in  urea-SDS  buffer  [29].  The
samples were analyzed with 10% SDS-polyacrylamide gel
electrophoresis  and  western  blotted  using  horseradish
peroxidase  (HRP)-conjugated  antibodies  against  myc  (BD
Biosciences,  San  Jose,  CA)  recognizing  CRYAA,
glyceraldehyde-3-phosphate  dehydrogenase  (GAPDH;
Sigma), or β-actin (Sigma), or monoclonal antibodies against
binding immunoglobulin protein (BiP; BD BioSciences), C/
EBP homologous protein/growth arrest and DNA damage-
inducible gene 153 (CHOP/GADD153; Santa Cruz Biotech,
Santa  Cruz,  CA),  caspase-3  (Santa  Cruz  Biotech),  or
phosphorylated  ER  kinase  (PERK;  Santa  Cruz  Biotech),
followed  by  appropriate  HRP-conjugated  immunoglobulin
(Ig) secondary antibodies. Signals were detected by enhanced
chemiluminescence (Amersham, Bucks, UK).
Immunofluorescence:  Cells  were  fixed  with  2%  neutral
buffered  paraformaldehyde  (Sigma)  in  0.1  M  PBS,
permeabilized and detected with mouse monoclonal anti-myc
(recognizing  CRYAA;  Sigma)  or  anti-protein  disulfide
TABLE 1. SENSE OLIGONUCLEOTIDES FOR SITE-DIRECTED MUTAGENESIS IN CRYAA.
Mutation Oligonucleotides (sense, 5’ to 3’; bold underlined letters indicate specific base change) Expression constructs
R12C (c.34C>T) ATCCAGCACCCCTGGTTCAAGTGCACCCTGGGGCCCTTCTAC pHis/myc-CRYAAR12C
R21L (c.62C>T) TGGGGCCCTTCTACCCCAGCCTGCTGTTCGACCAGTTTTTCG pHis/myc-CRYAAR21L
R49C (c.145C>T) TCCACCATCAGCCCCTACTACTGCCAGTCCCTCTTCCGCACCG pHis/myc-CRYAAR49C
G98R (c.292G>A) GTGGAGATCCACAGAAAGCACAACGAG pHis/myc-CRYAAG98R
R116C (c.346C>T) ACATTTCCCGTGAGTTCCACTGCCGCTACCGCCTGCCGTCC pHis/myc-CRYAAR116C
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2830isomerase  (PDI)  antibody  (BD  BioSciences)  followed  by
appropriate fluorescence-conjugated IgG secondary antibody
(Invitrogen)  and  4'-6-diamidino-2-phenylindole  (DAPI;
Sigma)  staining.  For  semiquantitative  evaluation  of
cytoplasmic CRYAA aggregates, >200 cells per sample were
analyzed. We graded CRYAA aggregation from 0 to 3+: 0,
no aggregate; 1+, few dot-like aggregates; 2+, more dot-like
aggregates, and 3+, extensive large aggregates. The staining
index, indicative of phenotype severity, was calculated using
the formula: 4(3+)% + 2(2+)% + 1(1+)% [30].
Transcription analysis: Total RNA was obtained by an RNA
purification kit (RNeasy kit, Qiagen, Valencia, CA) and an
on-column  DNase  digestion  kit  (RNase-free  DNase  kit,
Qiagen).  cDNA  from  1  μg  RNA,  10  ng/ml  random
hexanucleotide primer (Invitrogen), and reverse transcriptase
(SuperScript  III,  Invitrogen)  was  amplified  for  CRYAA,
hsp70, and hsp90 as well as other stress markers (Table 2).
Terminal apoptosis assay: Fixed cells were stained for myc
and  red  X-conjugated  secondary  antibody  (Jackson
ImmunoRes  Lab,  West  Gloves,  PA),  and  nuclei  were
counterstained  with  DAPI.  Samples  were  examined  by
fluorescence  microscopy  (DMRB  microscope;  Leica,
Wetzlar, Germany) equipped with a color imaging system
(Spot  RT,  Diagnostic  Instruments,  Sterling  Heights,  MI).
Terminal apoptosis rate was represented as percentage of cells
with  fragmented  nuclei.  For  each  experiment  (n=3),  ten
random images (40× objective) were analyzed.
RESULTS
Expression of cataract-causing mutant CRYAA variants in B3
cells: A repertoire of congenital cataract-causing CRYAA
mutants (R12C, R21L, R49C, G98R, and R116C) and WT
CRYAA were cloned into the pcDNA6-His/myc expression
vector and verified by sequencing. Each construct was then
transfected to human lens epithelial B3 cells. At 48 h, the cells
were collected in 0.5% Tx lysis buffer and fractionated to Tx-
soluble and Tx-insoluble proteins. By western blotting for
myc, representing CRYAA, most His/myc-tagged CRYAA
mutants were Tx-soluble, whereas His/myc-G98R CRYAA
was  predominantly  Tx-insoluble  (Figure  1A).  By  band
densitometry analysis, the average Tx solubilities were 98%
for WT CRYAA, 95% for R12C, 96% for R21C, 68% for
R49C, 96% for R116C, and 1.6% for G98R CRYAA in B3
cells.  Hence,  the  solubility  of  G98R  CRYAA  was
substantially reduced when compared to WT and other known
mutants. This insolubility was consistently observed upon
transfection with different ratios of pHis/myc-CRYAAG98R
DNA  to  FuGene  reagent.  The  transfection  efficiency  was
similar among WT and all studied mutants, as verified by
immunofluorescence  of  myc,  representing  CRYAA.  The
efficiency was maintained at about 50% at day 2 for sample
collection.
Localization  of  G98R  CRYAA  in  B3  cells:  The
immunofluorescence  study  showed  that  His/myc-G98R
CRYAA formed large-sized cytoplasmic aggregates (Figure
1D),  whereas  WT  CRYAA  was  located  diffusely  in  the
cytoplasm  (Figure  1C).  To  localize  the  His/myc-G98R
CYRAA,  we  performed  confocal  double
immunofluorescence.  The  aggregated  G98R  CYRAA  was
intensively  co-localized  with  PDI,  an  ER  resident  protein
(Figure 1E-H). In contrast, WT CRYAA exhibited mild co-
distribution with PDI. This demonstrated for the first time that
mutant  CRYAA  formed  insoluble  aggregates  in  the  ER.
Hence,  we  suggested  that  the  misfolded  mutant  G98R




Specific primer sequences (5’ to 3’) Product
size (bp)
αA-crystallin (CRYAA) U05569 F: CGGGACAAGTTCGTCATCTT 203
    R: GCAGACAGGGAGCAAGAGAG  
Heat-shock protein 70 (Hsp70) NM05345 1F: AAGTACAAAGCGGAGGACG 249
    1R: GATGGGGTTACACACCTGC  
    2F: TGCTGATCCAGGTGTACGAG 185
    2R: CGTTGGTGATGGTGATCTTG  
Heat-shock protein 90α (Hsp90α)) NM005348.3 F: ACCCAGACCCAAGACCAACCG 141
    R: ATTTGAAATGAGCTCTCTCAG  
Superoxide dismutase (SOD) NM000454.4 F: AGGGCATCATCAATTTCGAGC 430
    R: CAAGGGAATGTTTATTGGGCG  
αB-crystallin (CRYAB) NM001885.1 F: TCACCTAGCCACCATGGACATCGCCA 541
    R: CAAAAGCTTATTACTATTTCTTGGGGG  
Metallothionein 1M (MT) NM176870.2 F: GCAAAGAGTGCAAATGCACCTC 125
    R: TCAGGCACAGCAGCTGCACT  
Interleukin-6 (IL-6) NM000600.2 F: CTGGTCTTTTGGAGTTTGAGGTATACC 295
    R: CCATGCTACATTTGCCGAAGA  
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) BC014085 F: GAAGGTGAAGGTCGGAGT 225
    R: GAAGATGGTGATGGGATTTC  
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2831CRYAA-induced presenile cataract could be an ER storage
disease.
G98R  CRYAA  aggregated  in  cytoplasm  but  reduced  by
trimethylamine N-oxide: We hypothesized that the misfolding
of  G98R  CRYAA  with  the  exposed  hydrophobic  peptide
patches could be rectified by treatment with TMAO, which is
an osmolyte with a hydrophobic nature and acts as a chemical
chaperone  to  stabilize  proteins  with  a  tightly  packed
conformation. To authenticate this action, we also tested other
small molecule chemicals, 4-PBA, glycerol, and DMSO, by
virtue  of  the  chaperoning  activity  reported  previously
[31-37].  After  treatment  for  2  days  separately  with  these
chemicals,  we  examined  the  distribution  of  transfected
CRYAA. We found that both TMAO and 4-PBA treatments
resulted in fewer cells exhibiting large-sized myc-positive
aggregates (Figure 2B,C compared to untreated control in
Figure  2A).  The  majority  of  these  mutant  cells  had
cytoplasmic  punctate  staining.  A  scoring  analysis  showed
10% of the TMAO-treated mutant cells and 12% of the 4-
PBA-treated  mutant  cells  with  a  3+  level  of  aggregation
(Figure 2D). This was highly contrasted to approximately
75% of mutant cells before treatment (graded as 3+). The
staining index, representing the phenotype severity, was also
dramatically  reduced  after  TMAO  or  4-PBA  treatment,
approaching  that  of  WT-expressing  cells  (Figure  2E).
Treatment with 0.5 or 1% DMSO was ineffective in reducing
His/myc-G98R  CRYAA  aggregates.  Also,  toxicity  was
observed in cells treated with 1% or 5% of glycerol.
Trimethylamine  N-oxide  reduced  Triton  X-100-insoluble
G98R CRYAA: Treatment with 100 mM TMAO or 1 mM 4-
PBA  for  2  days  reduced  Tx-insoluble  His/myc-G98R
CRYAA, whereas the expression of His/myc-WT CRYAA
Figure 1. G98R αA-crystallin was TritonX-100-insoluble and formed aggregates inside cells. A: Triton X-100 (Tx) solubility assay of wild-
type (WT) and cataract-causing mutant CRYAA in B3 cells by western blotting of myc (detecting CRYAA), housekeeping GAPDH, and β-
actin. The band densitometry analysis showed the drastic reduction of Tx solubility of G98R CRYAA when compared to WT or other mutants.
B: Direct sequencing of pHis/myc-CRYAAG98R to indicate the base change at c.292G>A. C–L: Confocal double immunofluorescence of WT
and G98R CRYAA in B3 cells. C and D: A lower magnification to show the expression of WT (C) and G98R CRYAA (D) in cells. E–H:
G98R CRYAA (myc staining in F) formed intracellular aggregates and was intensely co-distributed with PDI (G) in the overlay image (H).
I–L: WT CRYAA (J, myc staining) was diffusely distributed in cytoplasm and had only mild co-distribution with PDI (K) in overlay image
(L). Nuclei were stained with DAPI (blue, E and I). Scale bars: 10 μm (C–L). PDI: protein disulphide isomerase; DAPI: 4'-6-diamidino-2-
phenylindole.
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2832was unaffected (Figure 3A). The percentage of Tx-insoluble
mutant protein after TMAO or 4-PBA treatment was similarly
decreased to almost one-fourth of that in untreated cells (22%
for  TMAO  treatment  and  28%  for  4-PBA;  p<0.05,
independent Student t test; Figure 3B). When examined at 5
days,  4-PBA-treated  cells  had  notable  morphological
changes, whereas TMAO showed a slender fibroblast-like
morphology at more than 5 days, which could be maintained
for  about  10  days.  Due  to  the  undesirable  morphological
changes,  4-PBA  was  not  selected  in  further  experiments.
Treatment with 0.5% or 1% DMSO was again ineffective in
reducing the insoluble His/myc-G98R CRYAA (Figure 3B),
and  1%  or  5%  glycerol  killed  cells.  Hence,  DMSO  and
glycerol were not used in subsequent experiments.
Figure 2. Chemical chaperones reduced the cellular aggregation of G98R αA-crystallin. A-C: Distribution of G98R αA-crystallin (CRYAA)
in transfected B3 cells. Untreated B3 cells showed aggregated G98R CRYAA (A), which was reduced after 4-PBA (1 mM; B) and TMAO
(100 mM; C) treatments. D: Semiquantitative scoring of intracellular CRYAA aggregates in cells. E: Staining index representing phenotype
severity showed dramatic reduction after 4-PBA or TMAO treatment. 4-PBA: 4-phenylbutyric acid; TMAO: trimethylamine N-oxide
Figure 3. Trimethylamine N-oxide reduced the detergent insolubility of C98R αA-crystallin (CRYAA). A: Western blot analysis of myc
(CRYAA) showed that the WT was mainly Tx-soluble and not affected by 4-PBA or TMAO treatment. Untreated G98R CRYAA was
predominantly Tx insoluble, which was significantly reduced after 4-PBA (1 mM) or TMAO (100 mM) treatment for 2 days. The asterisk
indicates a p<0.05 by independent Student  t test. DMSO (1%) did not affect mutant insolubility. B: TMAO reduced Tx-insoluble G98R
CRYAA dose dependantly. Treatment with TMAO (50 mM or higher) for 2 days significantly decreased Tx-insoluble G98R CRYAA. The
asterisk indicates a p<0.05 by independent Student t test. C: TMAO (100 mM) reduced Tx-insoluble G98R CRYAA in a time-dependant
manner. WT: wild-type; Tx: Triton X-100; 4-PBA: 4-phenylbutyric acid; TMAO: trimethylamine N-oxide; DMSO: dimethylsulfoxide.
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2833A 2-day treatment with TMAO at concentrations from 25
to 300 mM led to a dose-dependent decrease of Tx-insoluble
His/myc-G98R  CRYAA  (Figure  3C).  TMAO  at  25  mM
reduced Tx-insoluble G98R CRYAA to 83% (compared to
98%  for  untreated  mutant  protein).  Tx-insoluble  G98R
CRYAA was further reduced to 48% at 50 mM and to 24% at
100 mM treatment. The reduction was statistically significant
(p<0.05,  independent  Student  t  test).  Cell  death  became
prevalent  upon  treatment  with  TMAO  at  concentrations
higher than 200 mM. We further observed a time-dependent
decrease of Tx-insoluble His/myc-G98R CRYAA when cells
were treated with 100 mM TMAO (Figure 3D). At 12 h, the
level  decreased  to  67%  (compared  to  98%  for  untreated
mutant protein). It was further reduced to 28% at 24 h, 21%
at 48 h, and 3% at 72 h, and the reduction was statistically
significant (p<0.05, independent Student t test). It is notable
that while the insoluble G98R CRYAA decreased by TMAO
treatment, the level of soluble G98R did not increase. Hence,
we  postulated  that  TMAO  could  reduce  the  misfolded
polypeptides  of  CRYAA  via  degradation  rather  than  by
refolding them.
Trimethylamine N-oxide induced G98R CRYAA degradation
by  ubiquitin-proteasome  pathway  (UPP):  We  next
investigated  how  TMAO  reduces  Tx-insoluble  His/myc-
G98R CRYAA and resolves protein aggregates in the ER. In
the presence of 10 μM MG132, a reversible inhibitor of UPP,
in the transfected cell culture for 8 h, a substantial increase of
Tx-insoluble His/myc-G98R CRYAA protein was observed
(Figure 4A), and the reduced level of Tx-insoluble G98R
CRYAA after TMAO (100 mM, 2 days) was reversed by
MG132 (10 μM, 8 h). This indicated that G98R CRYAA
protein could be degraded via UPP. Blocking of UPP resulted
in more insoluble protein and augmented the mutant CRYAA
aggregation in cells, as demonstrated by immunofluorescence
(Figure 4D, compared to non-MG132-treated G98R cells in
Figure 4B). After treatment with 100 mM TMAO for 2 days,
a low level of Tx-insoluble mutant was again observed (Figure
4A).  The  levels  were  similar  as  in  previous  experiments.
Further incubation of these TMAO-treated cells with 10 μM
MG132 for 8 h increased Tx-insoluble CRYAA protein. This
was not significantly different from the untreated mutant cells.
Immunofluorescence showed that His/myc-G98R CRYAA
aggregates reappeared inside cells (Figure 4E, compared to
TMAO-treated cells in Figure 4C). We semiquantified the
cells  with  visible  intracellular  G98R  CRYAA  aggregates.
Nearly  all  MG132-treated  mutant  cells  showed  His/myc-
CRYAA aggregates (Figure 4F). The simultaneous treatment
with  TMAO  and  MG132  resulted  in  73%  of  cells  with
aggregates, which was similar to the untreated mutant cells
(81%). Only TMAO treatment significantly reduced the cells
with CRYAA aggregates to 36% (p<0.05 when compared to
untreated  cells  or  cells  with  both  TMAO  and  MG132
treatments). On the other hand, treatment with 10  μM 3-
methyladenine (3-MA, an inhibitor of autophagy) did not
show any change of His/myc-G98R CRYAA solubility and
subcellular aggregation (Figure 4G), indicating that CRYAA
was not a substrate of autophagy. In addition, the solubility
and subcellular aggregation of WT CRYAA was not affected
by treatment (data not shown).
Endoplasmic  reticulum  stress  and  apoptosis  caused  by
aggregated G98R CRYAA were alleviated by trimethylamine
N-oxide: We examined if TMAO affected the expression of
ER stress response proteins, including PERK and BiP, in
transfected B3 cells. These proteins were upregulated upon
His/myc-G98R CRYAA expression when compared to WT
CRYAA (Figure 5A). The expressions of PERK and Bip in
mutant-expressing  cells  were  increased  about  twofold
compared to the WT-expressing cells (PERK from 13% to
22%;  BiP  from  51%  to  92%).  B3  cells  incubated  with  a
transfection reagent had no observable changes. There was,
therefore,  induction  of  ER  stress  due  to  mutant  protein
expression. With TMAO (100 mM) treatment for 2 days, the
ER stress marker expression was substantially reduced to a
level about one-half of the untreated cells (p<0.05; Figure 5A).
The expression of PERK decreased from 22% to 7% and that
of Bip decreased from 92% to 47%. WT-expressing cells were
not affected by TMAO treatment, indicating that this chemical
chaperone acted on proteins that were not natively folded.
We further explored the consequence on apoptotic cell
death. Western blot analysis showed that CHOP/GADD153
and caspase-3 were upregulated in His/myc-G98R CRYAA-
expressing  B3  cells  nearly  twofold  compared  to  WT-
expressing cells (CHOP from 13% to 19%, caspase-3 from
20% to 29%; p<0.05; Figure 5A,B). This was accompanied
by an increased percentage of cells undergoing apoptosis and
showing  fragmented  nuclei  revealed  by  double
immunofluorescence  of  myc  (representing  CRYAA)  and
nuclear dye DAPI (G98R CRYAA cells 22% versus WT
CRYAA cells 6%; Figure 5C). Treatment with TMAO (100
mM) for 2 days resulted in reduced expression of both CHOP/
GADD153  and  caspase-3  (p<0.05;  Figure  5A,B).  The
expression of CHOP was decreased from 19% to 6% and that
of  caspase-3  from  2%  to  18%.  Consistent  results  were
obtained in experiments done in triplicate. The suppression of
apoptotic proteins was supported by a lower percentage of
cells  with  fragmented  nuclei  in  TMAO-treated  G98R
CRYAA cells (13% versus 22% in untreated G98R CRYAA
cells; Figure 5C). TMAO treatment of WT cells did not induce
changes  in  apoptotic  protein  expression  or  in  amounts  of
apoptotic cells (Figure 5B,C).
Effect  of  trimethylamine  N-oxide  treatment  on  cell  stress
signaling: We sought to examine if TMAO treatment (100
mM, 48 h) affected pathways of stress signaling on G98R
CRYAA cells. We studied gene expressions involved in heat-
shock responses, including Hsp70 and 90α, and cell stress
responses.  By  semiquantitative  PCR  we  confirmed  an
upregulation of Hsp70 by using two different pairs of specific
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2834primers, Hsp70 (1) and Hsp70 (2) (Figure 6). No change was
observed  for  Hsp90α  expression.  In  nontransfected  cells,
Hsp70  and  Hsp90  expression  was  not  altered  by  TMAO
treatment (Figure 6). On the other hand, gene expression of
cell  stress  signaling  (superoxide  dismutase  SOD  and  αB-
crystallin CRYAB for oxidative stress, metallothionein MT for
heavy  metal-induced  stress,  and  interleukin-6  IL6  for
inflammatory-associated stress) was unaffected by TMAO.
DISCUSSION
In  this  study,  we  expressed  the  presenile  cataract-causing
G98R CRYAA in lens epithelial B3 cells by transfection. The
mutant protein was found to be insoluble upon Tx extraction
and prone to be retained and form aggregates in the ER of
cells. This induced ER stress, and cells underwent apoptosis.
This is the first time it has been shown that the misfolded
G98R CRYAA-induced presenile cataract could be an ER
storage  disease.  This  cellular  defect  was  corrected  by
treatment with a chemical chaperone, the natural osmolyte
TMAO. Upon treatment, the Tx insolubility was reduced dose
and time dependently, and the cells had less mutant protein
aggregates, probably degraded via the ubiquitin proteasome
pathway.  TMAO  treatment  alleviated  the  ER  stress  and
apoptosis. We also showed that TMAO treatment modulated
hsp70 expression, which could be an underlying mechanism
of how this chemical chaperone affected the protein folding
environment in cells.
Unlike WT CRYAA, cataract-causing G98R CRYAA
protein  was  exclusively  partitioned  to  the  Tx-insoluble
fraction  and  formed  inclusion  bodies  when  expressed  in
Figure 4. Trimethylamine N-oxide treatment degraded reduced G98R αA-crystallin (CRYAA) via the ubiquitin-proteasome pathway. A:
Reduced level of Tx-insoluble G98R CRYAA after TMAO (100 mM, 2 days) was reversed by MG132 (10 μM, 8 h). MG132 alone further
increased Tx-insoluble mutant protein. B–E: Cytoplasmic G98R CRYAA aggregates were reduced after TMAO treatment (C). Intense
aggregation was observed in cells treated with TMAO and MG132 (E), MG132 only (D), and untreated cells (B). F: Percentages of cells with
CRYAA aggregates after treatments. G: Null changes of Tx-insoluble G98R CRYAA after treatment with 3-MA, unlike that of MG132
treatment. The asterisk indicates a p<0.05 by independent Student t test. Tx: Triton X-100; TMAO: trimethylamine N-oxide; UPR: unfolded
protein response; PERK: phosphorylated protein kinase-like ER-kinase; BiP: binding immunoglobulin protein; CHOP/GADD153: C/EBP
homologous protein/growth arrest and DNA damage-inducible gene 153; WT: wild-type.
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2835bacterial cells [19]. We extended this observation to human
lens  epithelial  B3  cells  and  discovered  that  Tx-insoluble
G98R CRYAA mutant protein formed large ER-associated
aggregates. The mutation from glycine to arginine induces a
gain  of  positive  charge,  and  the  encoded  protein  is  not
optimally folded. The Bis-ANS binding assay has illustrated
that the mutant protein has exposed hydrophobic sites that
cause it to become aggregation prone with the formation of
large  mixed  oligomers  with  WT  CRYAA  [19].  In  our
experiment we further showed that aggregation of His/myc-
G98R CRYAA induced ER stress, as demonstrated by PERK
and  BiP  upregulation.  The  mutant  protein  was  modestly
degradable by UPP. Application of the proteasome inhibitor
MG132 resulted in an increased level of Tx-insoluble mutant
protein. The prolonged ER overloading ultimately caused the
cells  to  undergo  apoptosis  through  a  caspase-3-dependent
pathway,  in  association  with  increased  CHOP/GADD153
expression. Our novel observation underlines the aggregation
of  mutant  CRYAA  and  subsequent  cell  death  as  a  major
pathogenetic factor for the development of lens opacity in
cataract.  On  the  other  hand,  other  mutants,  except  R49C
localized  in  both  nuclear  and  cytoplasmic  compartments
[23],  were  mainly  restricted  in  the  cytoplasm  without
aggregate formation [38]. This delineates the severity of the
highly aggregation-prone G98R mutant in cataract formation,
Figure 5. Trimethylamine N-oxide treatment alleviated the endoplasmic reticulum (ER) stress and apoptosis of cells expressing G98R αA-
crystallin (CRYAA). A: TMAO (100 mM, 2 days) reduced expression of ER stress and UPR markers (PERK, BiP, and CHOP/GADD153)
that were upregulated in G98R CRYAA cells. No specific change was observed for WT cells. B: Reduced caspase-3 expression in G98R
CRYAA cells treated with TMAO. The asterisk indicates a p<0.05 by independent Student t test. C: Fewer G98R CRYAA cells exhibited
fragmented nuclei after TMAO treatment.
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2836and ways to reduce aggregation could alleviate the disease
phenotype.
In  recent  years  chemical  chaperoning  on  misfolded
proteins has been shown to prevent or correct protein’s non-
native  conformation,  alleviating  mistrafficking  and  the
associated cellular defects, which resulted in enhanced cell
survival [39-42]. Although the exact mechanisms are still
undefined,  chemical  chaperones  likely  shift  the  folding
equilibrium of substrate proteins to a more native state, reduce
nonproductive  aggregation,  or  enhance  the  resident
chaperoning environment, allowing the misfolded proteins to
break away from ER retention and facilitate the transport
across intracellular compartments. This has been shown in
correcting a variety of misfolded proteins associated with
pathologic  conditions  and  renders  the  chaperone-assisted
protein rescue an appealing strategy to treat protein-folding
diseases [34,35,43]. Removal of aberrant accumulation of
misfolded proteins reduced cellular toxicity and enhanced cell
survival [34,44-46].
In  this  study,  we  applied  TMAO  and  other  chemical
chaperones  that  have  been  reported  previously  for  eye-
associated  proteins  to  WT  or  G98R-CRYAA-expressing
cells. Despite glycerol and DMSO causing significant cell
death, TMAO and 4-PBA at the usage levels were nontoxic,
which agreed with previous observations [47]. However, 4-
PBA was not optimal due to the fibroblastic morphology of
treated cells after long-term incubation. TMAO at optimal
concentrations of 50–100 mM reduced Tx-insoluble CRYAA
and  resolved  His/myc-G98R  CRYAA  aggregates  in  cells.
These  dosages  were  similar  to  our  previous  report  on
correcting the mutant myocilin [46]. The drug effect was
mediated  through  UPP-associated  degradation  and  was
reversed by MG132 inhibition. It has been known that proper
UPP function is essential for lens fiber cell differentiation
[48], in addition to its general regulation in protein quality
control, removal of obsolete proteins, cell cycle progression,
DNA repair, immune responses, and so on [49]. Defective
UPP leads to abnormal protein degradation, affecting protein
biosynthesis  and  processing,  and  more  severely,  causes
atypical protein accumulation and stress induction. This has
been  implicated  in  different  human  diseases,  such  as
Parkinson’s disease, Alzheimer’s disease, cancers, and so on
[50,51]. CRYAA is a substrate of UPP, and truncated mutant
CRYAA was reported to undergo rapid degradation by UPP
to prevent its accumulation in lens cells [29]. However, G98R
CRYAA was only moderately degradable by UPP and prone
to aggregation [19]. With TMAO treatment it appeared that
TMAO either promoted the degradation of His/myc-G98R
Figure 6. Heat-shock response and cell stress signaling. Semiquantitative reverse transcription-polymerase chain reaction analysis showed
specific upregulation of Hsp70 in G98R CRYAA cells treated with TMAO, whereas other stress-inducible genes remained unchanged. No
changes  were  found  for  TMAO  treatment  on  nontransfected  cells.  Hsp70:  heat-shock  protein  70;  CRYAA:  αA  crystallin;  TMAO:
trimethylamine N-oxide
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2837mutant through UPP or resolved the protein aggregation in the
ER, hence reducing cellular stress. This was substantiated by
reduced expression of the ER stress markers, PERK and BiP,
as well as the pro-apoptotic proteins, caspase-3 and CHOP/
GADD153. On the other hand, 3-MA treatment did not affect
G98R CRYAA aggregation in cells suggesting that G98R
CRYAA was not a substrate of autophagy.
TMAO is a naturally occurring osmolyte present in deep-
water  fishes.  It  is  important  to  counteract  the  protein
destabilizing effect of urea and hydrostatic pressure. Its action
on  protein  folding  or  stabilization  could  be  due  to  its
hydrophobic nature to push water molecules to the protein
surface. This increased hydration affects Gibbs free energy
(G)  levels  along  the  protein-folding  process  so  that  ∆G
between  native  and  denatured  states  becomes  larger  and
drives  the  equilibrium  toward  the  native  state  [48].  The
solvent-accessible surface area is reduced and causes a tighter
packing  of  polypeptides  or  reduces  the  mobility  between
protein  domains,  leading  to  a  more  stabilized  protein
conformation  and  oligomeric  assembly  [52].  The  mutated
G98R CRYAA had exposed hydrophobic patches [19] which
could be modified or removed by TMAO, resulting in a more
stabilized conformation, likely recognized by UPP and were
being degraded.
In  addition,  we  uncovered  another  TMAO-initiated
cytoprotection  pathway  that  induced  Hsp70  expression,
which  is  critical  for  cell  survival.  Hsp70  is  a  molecular
chaperone widely expressed in cells and functions to modulate
the  engagement  and  progression  of  apoptosis  induced  by
various stimuli [53]. Hsp70 suppresses apoptosis by directly
blocking  the  assembly  of  functional  Apaf-1  apoptosomes
[54]. It also helps proteins to fold through repeated cycles of
substrate  binding  and  release.  The  stress-inducible  Hsp70
helps cells cope with adverse conditions, in part by aiding in
the folding of nascent polypeptides or refolding damaged
proteins, preventing or reversal of protein aggregation, or
promoting  protein  trafficking  [55-58].  We  observed  an
improvement of mutant cell survival in our study. It appears
that TMAO either stabilizes G98R CRYAA and promotes its
UPP-associated degradation or modulates the protein-folding
environment  and  reduces  apoptosis  through  heat-shock
response signaling. We could not determine if changes of
Hsp70 expression were directly caused by TMAO treatment,
which might involve a change of chaperoning capacity in
cells, or a consequence of mutant protein stabilization. Our
previous study also identified a delayed Hsp70 expression
after heat-shock induction in R12C CRYAA-expressing cells
[27]. Further work would provide better characterization of
Hsp70 regulation in cataract pathogenesis and may introduce
possible treatment strategies. The effect of TMAO on other
cell  stress  signaling  (including  metal-induced  stress  and
inflammatory stress) was not observed.
In conclusion, our study revealed cellular aggregation
and ER stress induced by misfolded G98R mutant CRYAA in
lens epithelial cells, and this caused apoptosis. These defects
were alleviated by the natural osmolyte TMAO. Our findings
provide a basis for a new chemical-based strategy to alleviate
cell stress and improve cell survival.
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